{"pmid":32340070,"title":"ACE inhibitors and COVID-19: We don't know yet.","text":["ACE inhibitors and COVID-19: We don't know yet.","J Card Surg","Khashkhusha, Taqua R","Chan, Jeffrey Shi Kai","Harky, Amer","32340070"],"journal":"J Card Surg","authors":["Khashkhusha, Taqua R","Chan, Jeffrey Shi Kai","Harky, Amer"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32340070","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jocs.14582","keywords":["acei","covid-19","coronavirus"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1665264685567442944,"score":8.574329,"similar":[{"pmid":32292227,"pmcid":"PMC7151242","title":"[Controversy regarding ACE inhibitors / ARBs in Covid-19].","text":["[Controversy regarding ACE inhibitors / ARBs in Covid-19].","Rev Esp Cardiol","Soria Arcos, Federico","Romero-Puche, Antonio","Vicente Vera, Tomas","32292227"],"journal":"Rev Esp Cardiol","authors":["Soria Arcos, Federico","Romero-Puche, Antonio","Vicente Vera, Tomas"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292227","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.recesp.2020.03.014","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664636192731168769,"score":97.58431},{"pmid":32292884,"pmcid":"PMC7140724","title":"Important Steps to Control COVID-19/SARS-CoV-2 Infection.","text":["Important Steps to Control COVID-19/SARS-CoV-2 Infection.","Elderly patients are having high mortality rates from COVID-19/SARS-CoV-2 infection compared to younger patients. The SARS-CoV-2 virus uses the ACE2 receptor as the entry point to the host cells. ARBs/ACEIs which are widely used in elderly patients, have been found to be associated with overexpression of ACE2.To decrease the severity of COVID-19 infection, ARB/ACEI should be switched to another class drug not known to cause a rise in ACE2 until the COVID-19 infection subsides. Specific human immunoglobulin can be tried for COVID-19 patients with critical conditions under supervision.","SN Compr Clin Med","Chatterjee, Sudipto","32292884"],"abstract":["Elderly patients are having high mortality rates from COVID-19/SARS-CoV-2 infection compared to younger patients. The SARS-CoV-2 virus uses the ACE2 receptor as the entry point to the host cells. ARBs/ACEIs which are widely used in elderly patients, have been found to be associated with overexpression of ACE2.To decrease the severity of COVID-19 infection, ARB/ACEI should be switched to another class drug not known to cause a rise in ACE2 until the COVID-19 infection subsides. Specific human immunoglobulin can be tried for COVID-19 patients with critical conditions under supervision."],"journal":"SN Compr Clin Med","authors":["Chatterjee, Sudipto"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292884","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s42399-020-00271-7","keywords":["ace2","acei","arb","covid-19","sars-cov-2"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1664636192514113536,"score":91.17332},{"pmid":32337113,"pmcid":"PMC7179986","title":"Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2.","text":["Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease of 2019 (COVID-19). First identified in Wuhan (Hubei, China) in December of 2019, it has since been declared a pandemic by the World Health Organization in March of 2020. In this study, we will provide a brief review of viral origin, identification, symptoms, transmission, diagnosis, and potential treatment strategies for the newly identified SARS-CoV-2 strain.","Cureus","Valencia, Damian N","32337113"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease of 2019 (COVID-19). First identified in Wuhan (Hubei, China) in December of 2019, it has since been declared a pandemic by the World Health Organization in March of 2020. In this study, we will provide a brief review of viral origin, identification, symptoms, transmission, diagnosis, and potential treatment strategies for the newly identified SARS-CoV-2 strain."],"journal":"Cureus","authors":["Valencia, Damian N"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337113","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7759/cureus.7386","keywords":["2019-ncov","acei","arb","chloroquine","corona virus","corticosteroids","covid-19","novel coronavirus","remdesivir","sars-cov-2"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment","Transmission","Mechanism"],"weight":1,"_version_":1665264685439516672,"score":91.15655},{"pmid":32320478,"title":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence.","text":["Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence.","Concerns have been raised regarding the safety of Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in patients with COVID-19, based on the hypothesis that such medications may raise expression of ACE2, the receptor for SARS-CoV-2. We conducted a literature review of studies (n=12) in experimental animals and human subjects (n=12) and evaluated the evidence regarding the impact of administration of ACEIs and ARBs on ACE2 expression. We prioritized studies that assessed ACE2 protein expression data, measured directly or inferred from ACE2 activity assays. The findings in animals are inconsistent with respect to an increase in ACE2 expression in response to treatment with ACEIs or ARBs. Control/sham animals show little to no effect in the plurality of studies. Those studies that report increases in ACE2 expression tend to involve acute injury models and/or higher doses of ACEIs or ARBS than are typically administered to patients. Data from human studies overwhelmingly imply that administration of ACEIs/ARBs does not increase ACE2 expression. Available evidence, in particular, data from human studies, does not support the hypothesis that ACEI/ARB use increases ACE2 expression and the risk of complications from COVID-19. We conclude that patients being treated with ACEIs and ARBs should continue their use for approved indications.","Clin Pharmacol Ther","Sriram, Krishna","Insel, Paul A","32320478"],"abstract":["Concerns have been raised regarding the safety of Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in patients with COVID-19, based on the hypothesis that such medications may raise expression of ACE2, the receptor for SARS-CoV-2. We conducted a literature review of studies (n=12) in experimental animals and human subjects (n=12) and evaluated the evidence regarding the impact of administration of ACEIs and ARBs on ACE2 expression. We prioritized studies that assessed ACE2 protein expression data, measured directly or inferred from ACE2 activity assays. The findings in animals are inconsistent with respect to an increase in ACE2 expression in response to treatment with ACEIs or ARBs. Control/sham animals show little to no effect in the plurality of studies. Those studies that report increases in ACE2 expression tend to involve acute injury models and/or higher doses of ACEIs or ARBS than are typically administered to patients. Data from human studies overwhelmingly imply that administration of ACEIs/ARBs does not increase ACE2 expression. Available evidence, in particular, data from human studies, does not support the hypothesis that ACEI/ARB use increases ACE2 expression and the risk of complications from COVID-19. We conclude that patients being treated with ACEIs and ARBs should continue their use for approved indications."],"journal":"Clin Pharmacol Ther","authors":["Sriram, Krishna","Insel, Paul A"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320478","week":"202017|Apr 20 - Apr 26","doi":"10.1002/cpt.1863","keywords":["ace inhibitors","ace2","angiotensin ii","angiotensin receptor blockers","covid-19"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664815087847735297,"score":89.01089},{"pmid":32226946,"pmcid":"PMC7086482","title":"COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't.","text":["COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't.","Microbiol Aust","Mackenzie, John S","Smith, David W","32226946"],"journal":"Microbiol Aust","authors":["Mackenzie, John S","Smith, David W"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32226946","week":"202014|Mar 30 - Apr 05","doi":"10.1071/MA20013","source":"PubMed","topics":["Mechanism","Transmission","Diagnosis","Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640912684220416,"score":85.068245}]}